TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00778453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-based mCIT
Description: restraint of the unaffected arm and practice of the affected arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-based BIT
Description: bilateral symmetric, repetitive arm training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-based TR
Description: hospital-based traditional rehabilitation : OT or PT or therapist-based training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based mCIT
Description: restraint of the unaffected arm and practices of the affected arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based BAT
Description: bilateral symmetric, repetitive arm training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based TR
Description: home-based traditional rehabilitation:OT or PT or therapist-based training
Study: NCT01751633

Intervention type: PROCEDURE
Intervention: Surgical

Intervention type: PROCEDURE
Intervention: Conservative treatment
Study: NCT03407833

Intervention type: OTHER
Intervention: Endoscopy biopsy
Description: Tissue samples will be collected from the jejunum, duodenum, and colon during the subject's standard of care procedure.

Intervention type: OTHER
Intervention: Endoscopy biopsy
Description: Tissue samples will be collected from the jejunum, duodenum, and colon during the subject's standard of care procedure.

Intervention type: OTHER
Intervention: Surgical biopsy
Description: Biopsy of the liver is standard of care for diagnosing NAFLD. Biopsy of omentum, skeletal muscle and subcutaneous adipose (the latter two tissues taken at the site of trocar placement) will be collected intraoperatively at the time of Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG).

Intervention type: OTHER
Intervention: Mixed-meal tolerance test
Description: The mixed meal tolerance test (MMTT) shows how much insulin your body is making after drinking a liquid meal beverage that contains fats, protein and carbohydrates (sugar). Glucose, C-peptide, free fatty acids, triglycerides, incretins, pancreatic polypertide, bile aceis, and fatty acid amides can also be measured. A total of 9 tablespoons of blood is taken over a 255 minute period.
Study: NCT03337893

Intervention type: DIAGNOSTIC_TEST
Intervention: blood pressure
Description: it will be done both right and left arms

Intervention type: DIAGNOSTIC_TEST
Intervention: blood pressure
Description: it will be done both right and left arms
Study: NCT00105040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PB)
Description: Oral tablets and oral solution
Study: NCT02896296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.
Study: NCT04664751

Intervention type: OTHER
Intervention: Nil-per-Oral
Description: NPO details
Study: NCT01825694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused Substance Abuse Intervention
Description: An integrated treatment approach to reduce substance use and PTSD symptoms. The intervention program includes: 1) 1-2 individual sessions during which youth talk about the trauma, during the course of the intervention program; 2) 16 group sessions for youth; 3) 2 conjoint sessions with parents to improve communication and problem-solving skills; and 4) 2 parent-education group sessions.
Study: NCT01273467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 0007 or placebo (Stage A)
Description: a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 0007 or placebo (Stage B)
Description: a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
Study: NCT05936047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vertebral bone marrow clot
Description: vBMA will be harvested from each patient vertebral pedicle with the preparation of the site for pedicle screw insertion during spinal surgery. After the positioning of pedicle screws, the decompression of the cauda and nerve roots will be achieved with a hemilaminectomy and foraminotomy. vBMA clot will be opposed on the hemi-laminae and transvers process on the contralateral side of the hemilaminectomy. On the hemilaminectomy side, foramino-arthrectomy will be performed to insert the interbody fusion cage if necessary. After aspiration, the vBMA will be clotted and used for surgical procedure. vBMA clot will be applied on each side of the vertebra according to the number of segments to be fused.
Study: NCT03407833

Intervention type: OTHER
Intervention: Excised Liver Tissue Sampling
Description: Tissue will be collected from the excised liver for research after the diseased liver has been removed as part of the standard of care procedure.
Study: NCT00538863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray
Description: Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual spray
Description: Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg
Study: NCT00201396

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CCRT
Description: Radiation with weekly Cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CCRT
Description: Radiation with weekly Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
Description: Induction C/T + CCRT
Study: NCT01751919

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib mesylate tablet 400 mg, 1 Tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib mesylate tablet 400 mg, 1 Tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Glivec film-coated tablet 100 mg, 4 Tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Glivec film-coated tablet 100 mg, 4 Tablets
Study: NCT05055713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+ beta blockers
Description: Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+ PSE+beta blockers
Description: Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).A standard dose of NSBB (carvedilol) was applied to patients according to the Baveno VI recommendations if there were no contraindications.Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Description: Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+ PSE
Description: Endoscopic variceal ligation (EVL) is for the secondary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+Somatostatin
Description: The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+PSE+Somatostatin
Description: The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
Study: NCT02704832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatrician Intervention
Description: Arm B : The duration of the geriatric intervention will be 12 months. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.
Study: NCT02582944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus BF-180 bronchoscope (standard adult)
Description: -Standard of care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veran Spinview Thoracic Navigation System
Description: -Electromagnetic navigation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus UM-S20-17S
Description: -Endobronchial ultrasound mini-probe

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Study: NCT03837158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early loading
Description: two TiZr implants on SLA surface

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate loading
Description: four TiZr implants on SLA surface
Study: NCT01790308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSII
Description: continuous subcutaneous insulin infusion for 2\~4 weeks
Study: NCT00387660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT02401555

Intervention type: DEVICE
Intervention: Geenius HIV1/2 Supplemental Assay
Description: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).

Intervention type: DEVICE
Intervention: Geenius HIV1/2 Supplemental Assay
Description: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).

Intervention type: DEVICE
Intervention: Geenius HIV1/2 Supplemental Assay
Description: The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).
Study: NCT02242890

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contraception Information Packet
Description: The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths.
Study: NCT03116347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cuvitru
Description: 200 mg/ml solution for Immune Globulin Subcutaneous Injection
Study: NCT02836600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally
Study: NCT03249493

Intervention type: OTHER
Intervention: Blood sample on DBS
Description: We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards.~HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results \> 1000 cp/mL

Intervention type: OTHER
Intervention: Blood sample on DBS
Description: We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards.~HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results \> 1000 cp/mL
Study: NCT05585788

Intervention type: DEVICE
Group type: OTHER
Intervention: Addinex Device (ADX-27)
Description: The device operates without the use of any electronics, wireless or firmware requirements. This is achieved through its mechanical system which uses a different randomized passcode for each dose that is loaded into a circular drum inside the device. The passcodes are provided by an online server through either a mobile app, web app, text service or call in service. The online server provides passcodes on a request basis, while following instructions set by the treating physicians.
Study: NCT02297282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Description: Behavioural activation is a therapy, which has been shown to be quite effective in the treatment of depression. Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
Study: NCT01395862

Intervention type: DRUG
Intervention: Salmeterol and Fluticasone
Study: NCT01880047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: Eltrombopag will be administered for 8 weeks or until the platelet count exceeds 150,000; at this point dosing will stop, subject will be considered a responder and the subject will eligible for entering Part 2 (the long term treatment part of the study. The dose at which the subject achieved the primary endpoint (\> 50,000 and increase by \> 20,000) will be considered the dose of response. Dose escalation will continue, despite satisfaction of the primary endpoint of study (\> 50,000 and \> 20,000 above baseline), unless the platelet count reaches the lower limit of normal range 150,000. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04245865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2800 mg/m2 iv

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorouracil
Description: 2800 mg/m2 iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate
Description: 400 mg/m2 iv

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium folinate
Description: 400 mg/m2 iv
Study: NCT00941382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine-Metformin
Description: sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sibutramine
Description: 15 mg per day for 180 days
Study: NCT04484519

Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging
Description: Functional Magnetic Resonance Imaging
Study: NCT04245865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 iv

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m2 iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg OR 7.5 mg/kg iv

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg OR 7.5 mg/kg iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000 mg/m2 orally daily for two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 2000 mg/m2 orally daily for two weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: 300 mg orally x 3 daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally x 3 daily
Study: NCT02762890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Description: neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular blockade
Description: neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
Study: NCT01292265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
Study: NCT04970589

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mango
Description: 400g of mango/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango
Description: 400g of mango/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango
Description: 400g of mango/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango
Description: 400g of mango/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 1 probiotics capsule/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: 1 probiotics capsule/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Placebo capsule/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 Placebo capsule/day
Study: NCT03588429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Anesthesia was maintained with isoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
Study: NCT01704573

Intervention type: DRUG
Intervention: 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine
Description: The study will be performed using an Investigational New Drug (IND) Application for the 2-\[18F\]FA radioligand. The 2-\[18F\]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-\[18F\]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-\[18F\]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-\[18F\]FA from the FDA.
Study: NCT05175378

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lifestyle intervention
Description: We investigated the potential cardiovascular health effects of the Mediterranean dietary pattern on adult women with relapsing-remitting multiple sclerosis, in regards to body weight, body composition, cardiovascular blood biomarkers (fasting glucose, lipids, C-reactive protein), as well as depression and anxiety levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: We investigated the potential cardiovascular health effects of the Mediterranean dietary pattern on adult women with relapsing-remitting multiple sclerosis, in regards to body weight, body composition, cardiovascular blood biomarkers (fasting glucose, lipids, C-reactive protein), as well as depression and anxiety levels.
Study: NCT00693511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit Training
Description: Circuit Training (aerobic + strength training 2 times per week for 16 weeks)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit training + motivational interviewing
Description: Circuit training (aerobic + strength training 2 times per week for 16 weeks) + motivational interviewing (4 individual + 4 group sessions)